Karmakar Tanusri, Mallick Sanjaya K, Chakraborty Arpita, Maiti Animesh, Chowdhury Subhankar, Bhattacharyya Maitree
Department of Biochemistry, and Center for Research in Nanoscience and Nanotechnology, University of Calcutta, Kolkata, India.
BD-CU Center of Excellence for Nanobiotechnology, Kolkata, India.
Clin Hemorheol Microcirc. 2015;59(1):67-81. doi: 10.3233/CH-141818.
Platelet signatures indicating differential dysfunction, hyperactivation, aggregation or adhesion are capable of expressing their characters during the journey of a disease process, and can be utilized as cost effective biomarkers with immense clinical value. Type 2 diabetes mellitus (T2DM) is a major lifestyle disease of contemporary world with progression to diabetes associated cardiovascular diseases (DM-CVD). We identified a few potential biomarkers in platelets of T2DM to analyze the thrombotic risk in diabetes subjects by utilizing flow cytometric quantification with different flurochrome conjugated monoclonal antibodies. Our study describes interesting correlations (p<0.0001) for different clinical parameters of concurrent threat for vessel occlusion and the status of indices like reactive oxygen species, von Willebrand factor and mitochondrial membrane potential using western blotting and fluorescence techniques. Our study involved 32 T2DM, and 31 T2DM-CVD subjects compared to 29 healthy controls without any history of T2DM or CVD. An altered expression of platelet surface markers P-selectin (CD62p) and GpIIb/IIIa (CD 41/61, PAC1) along with changes in the platelet size due to agonist induced activation contributed to the enhanced thrombotic potential in the patients. This work elucidates the prospect of platelet biomarkers as diagnostic tool to predict cardiovascular risk in DM subjects.
表明血小板功能异常、过度活化、聚集或黏附的特征在疾病进程中能够表现出来，并可作为具有巨大临床价值的高性价比生物标志物。2型糖尿病（T2DM）是当代主要的生活方式疾病，会发展为糖尿病相关心血管疾病（DM-CVD）。我们在T2DM患者的血小板中鉴定出一些潜在生物标志物，通过使用不同荧光素偶联单克隆抗体进行流式细胞术定量分析，以评估糖尿病患者的血栓形成风险。我们的研究利用蛋白质印迹法和荧光技术，描述了血管阻塞并发威胁的不同临床参数与活性氧、血管性血友病因子和线粒体膜电位等指标状态之间有趣的相关性（p<0.0001）。我们的研究纳入了32名T2DM患者和31名T2DM-CVD患者，并与29名无T2DM或CVD病史的健康对照者进行比较。血小板表面标志物P-选择素（CD62p）和糖蛋白IIb/IIIa（CD 41/61，PAC1）的表达改变，以及激动剂诱导激活导致的血小板大小变化，促使患者的血栓形成潜力增强。这项工作阐明了血小板生物标志物作为预测DM患者心血管风险诊断工具的前景。
